Xeris Pharmaceuticals, Inc.
Chicago, IL · CIK 0001346302 · Biotech · Public
DiazePen™, an auto-injectable subcutaneous diazepam formulation using proprietary XeriSol™ platform for rapid seizure treatment
xerispharma.com →- Grants
- $8.7M
- 10 awards
- Sector median: 1
- Raised
- $80M
- 5 Form D · May 2017
- 112 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 22 granted · 18 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201120122013201420152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,298,748 | |
| Private capital raised | Form D · SEC | $225,000 | |
| Private capital raised | Form D · SEC | $7,274,592 | |
| Federal grant | Department of Health and Human Services · Phase II · CSI Glucagon for Treatment of Congenital Hyperinsulinism | $485,403 | |
| Federal grant | Department of Health and Human Services · Phase II · Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia | $561,530 | |
| Federal grant | Department of Health and Human Services · Phase II · Auto-Injectable Diazepam Formulation for Rapid Treatment of Uncontrolled Seizures | $514,129 | |
| Private capital raised | Form D · SEC | $41,005,980 | |
| Federal grant | Department of Health and Human Services · Phase II · Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia | $816,080 | |
| Federal grant | Department of Health and Human Services · Phase II · Closed Loop Glucagon Pump for Treatment of Post Bariatric Hypoglycemia | $1,221,086 | |
| Federal grant | Department of Health and Human Services · Phase II · CSI Glucagon for Treatment of Congenital Hyperinsulinism | $1,587,798 | |
| Private capital raised | Form D · SEC | $30,050,443 | |
| Federal grant | Department of Health and Human Services · Phase II · Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia | $405,006 | |
| Federal grant | Department of Health and Human Services · Phase II · CSI Glucagon for Treatment of Congenital Hyperinsulinism | $754,662 | |
| Federal grant | Department of Health and Human Services · Phase II · Auto-Injectable Diazepam Formulation for Rapid Treatment of Uncontrolled Seizures | $1,591,098 | |
| Federal grant | Department of Health and Human Services · Phase II · Auto-Injectable Diazepam Formulation for Rapid Treatment of Uncontrolled Seizures | $793,851 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2212 | PARATEK PHARMACEUTICALS INC | — | $93M |
| 2213 | Milestone Pharmaceuticals Inc. | — | $91M |
| 2214 | BE COOL PHARMACEUTICS, LLC | — | — |
| 2215 | Xeris Pharmaceuticals, Inc. | — | $80M |
| 2216 | Avenzo Therapeutics | — | $79M |
| 2217 | Oragenics, Inc. | — | $67M |
| 2218 | Discidium Biosciences, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Doug BaumDirector
- Douglas BaumDirector · Executive Officer
- Shane BrisbinDirector
- Paul EdickDirector · Executive Officer
- Robert FaulkerDirector
- Brad HuckabeeExecutive Officer
- Phillip JohnsonExecutive Officer
- John KinzelDirector · Executive Officer
- John KinzellDirector · Executive Officer
- Cary McNairDirector
- Steven PrestrelskiDirector · Executive Officer
- Navneet PuriDirector
- Jonathan RigbyDirector
- Yash SabharwalExecutive Officer
- Mark SalimanExecutive Officer
- John ShannonExecutive Officer
- Poul StrangeExecutive Officer
- Timothy SullivanDirector
Patents
- Injectable High Concentration Pharmaceutical Formulations And Methods Of Manufacturing And Use Thereofapplication
- Treatment Of Exercise-induced Hypoglycemia In Type 1 And Insulin Using Type 2 Diabetesapplication
- Stable Levothyroxine Compositions In Aprotic Polar Solventsgranted
- Stable Levothyroxine Compositions In Aprotic Polar Solventsapplication
- Treatment Of Exercise-induced Hypoglycemia In Type 1 And Insulin Using Type 2 Diabetesgranted
- Stable Levothyroxine Compositions In Aprotic Polar Solventsgranted
- Methods Of Treating Disease With Levoketoconazoleapplication
- Methods Of Treating Disease With Levoketoconazolegranted
- Methods For Producing Stable Therapeutic Formulations In Aprotic Polar Solventsapplication
- Stable Therapeutic Compositions In Aprotic Polar Solvents And Methods Of Manufacturing The Sameapplication
- Stable Sustained Release Therapeutic Compositions In Aprotic Polar Solvents And Methods Of Manufacturing The Sameapplication
- Methods For Producing Stable Therapeutic Formulations In Aprotic Polar Solventsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.